Zydus Cadila receives final approval from USFDA for Butalbital, Acetaminophen and Caffeine Tablets

Zydus Cadila has received final approval from the USFDA to market Butalbital, Acetaminophen and Caffeine Tablets (US RLD: Butalbital, Acetaminophen and Caffeine Tablets) in the strengths 50mg/325mg/40 meg.

This combination of medication is used to treat symptom complex of tension (or muscle contraction) headache. The drug will be manufactured at Nesher Pharma's manufacturing facility at St. Louis, USA.

The group now has 294 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.377.25 as compared to the previous close of Rs. 360.95. The total number of shares traded during the day was 703720 in over 16246 trades.

The stock hit an intraday high of Rs. 378.5 and intraday low of 362. The net turnover during the day was Rs. 261384331.

Source : Equity Bulls

Keywords